Full-Time
Regional Sales Manager
Hybrid Therapies
Updated on 8/19/2026
AtriCure
1,001-5,000 employees
Sells ablation devices for atrial fibrillation
No salary listed
Paris, France
Hybrid
Travel required for 80% of working time.
Bachelor's
 Sales & Account Management (1) |
|---|
Get referred to AtriCure
See people who can refer or advise you
- A bachelor's degree or demonstrated equivalent combination of education, training, and experience is required.
- Specific knowledge and selling experience related to endocardial ablation systems and/or occluder systems is highly preferred.
- A successful track record with sales quota achievement is required.
- Strong clinical and technical aptitude is required.
- Excellent interpersonal skills and the ability to build personal relationships are required.
- Problem-solving and troubleshooting skills are required.
- The candidate must be confident, goal-oriented, self-motivated, and able to work as a team player.
- Strong, proven relationship-building skills are required.
- Computer experience with Microsoft PowerPoint, Outlook, Excel, and Word is required.
- The ability to travel 80% of working time is required.
- Experience selling in the medical device industry is required.
- Fluent French language skills are required.
- Develop, implement, and execute a strategic sales plan for the designated territory to achieve assigned targets.
- Schedule and meet with top hospital administration to present tools and initiatives highlighting AtriCure products and clinical approaches.
- Promote, establish, and support Centers of Excellence for appropriate hospital facilities.
- Continually identify new customers, contacts, and opportunities.
- Work closely with the Area Sales Director to implement and execute strategies to achieve corporate sales goals.
- Work with the marketing team to share industry news and trends and receive feedback.
- Attend industry trade shows and events as needed.
- Manage the assigned territory and track customer activity.
- Understand and satisfy the requirements for obtaining access to a hospital, healthcare system, or other client site.
- Specific knowledge and selling experience related to endocardial ablation systems and/or occluder systems.
- Successful sales history and experience in the electrophysiology market and call point.
AtriCure designs and sells medical devices to treat atrial fibrillation and related heart conditions. Its products include ablation systems, left atrial appendage management devices, and cryoablation tools used in open-heart and minimally invasive surgeries; these devices deliver energy to heart tissue to create precise lesions and manage blood flow. The company differentiates itself with an integrated AF-focused portfolio, combined with hands-on training and support for clinicians to ensure proper use in various surgical workflows. Its goal is to improve patient outcomes by providing reliable, easy-to-use devices and comprehensive clinician education.
Company Size
1,001-5,000
Company Stage
IPO
Headquarters
West Chester, Pennsylvania
Founded
1994
Get referred to AtriCure
See people who can refer or advise you
Simplify's Take
What believers are saying
- On July 23, 2026, AtriCure raised 2026 revenue guidance to $602 million-$610 million.
- Q2 2026 revenue hit $153.6 million, with adjusted EBITDA rising 78% to $27.3 million.
- BoxX-NoAF reached 50% enrollment ahead of schedule, with data expected in 2027.
What critics are saying
- Medtronic’s Affera Sphere-360 and Boston Scientific’s PFA systems attack AtriCure’s core surgery workflows.
- BoxX-NoAF and LeAAPS still define upside; any trial failure erases expansion plans.
- If PFA catheter adoption shifts surgeons away, AtriCure’s surgical ablation franchise shrinks permanently.
What makes AtriCure unique
- AtriCure’s EnCompass and AtriClip platforms bundle surgical ablation, appendage exclusion, and training.
- CryoSPHERE MAX halved freeze times and drove pain-management adoption in Q2 2026.
- LeAAPS enrolled 6,573 patients, giving AtriCure the largest cardiac-surgery device trial.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Health Savings Account/Flexible Spending Account
Wellness Program
401(k) Company Match
Parental Leave
Pet Insurance
Employee Stock Purchase Plan
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 0%1 year growth
↑ 0%2 year growth
↑ 0%AtriCure is targeting $1 billion in revenue by 2030, up from current guidance of $602–610 million annually. The company, which focuses on atrial fibrillation treatment and post-surgical pain management, has posted roughly 18% compound annual growth over five years, a 77% gross margin, and three consecutive quarters of net income. Pain management is driving expansion. Procedure volume grew about 25% in the latest quarter, aided by the cryoSPHERE MAX launch, which halves freeze time for certain procedures. Market penetration stands at around 20% in thoracic procedures, with room to grow in sternotomy and amputation applications. Clinical trials could expand AtriCure's market further. The BoxX-NoAF trial is expected to complete enrollment by year-end, with data due mid-2027. The larger LeAAPS trial may support broader AtriClip adoption if stroke-reduction results prove favourable.
AtriCure reported second-quarter fiscal 2026 earnings on 23 July, with revenue of $153.6 million and adjusted EPS of $0.18, beating consensus estimates by $1.79 million and $0.16 respectively. The medical device company swung to a net profit of $9 million from a loss of $6.2 million in the same quarter last year. Gross margin improved to 77.2%, up 270 basis points year-on-year, driven by product innovation and efficiencies. US business grew 14% whilst worldwide revenue rose 13%. The pain management franchise saw 27% growth. AtriCure raised its full-year 2026 revenue guidance to $602 million-$610 million and adjusted EBITDA guidance to $85 million-$89 million. The company is enrolling patients in clinical trials targeting the post-operative atrial fibrillation market, valued at over $2 billion annually.
AtriCure Inc reported strong second-quarter results with worldwide revenue of $154 million, representing 13% year-over-year growth. US revenue reached $125.6 million, up 13.6%, whilst international revenue grew 9.6% to $28 million. The medical device company achieved significant profitability improvements, posting net income of $9 million compared to a net loss of $6.2 million in the prior year. Adjusted EBITDA exceeded $27 million, with gross margin expanding to 77.2%. Pain management revenue led growth at 27.8% to $27.1 million, driven by adoption of cryoSPHERE MAX. Appendage management revenue increased 14.4% to $51.6 million, whilst open ablation revenue rose 12.1% to $40.9 million. The company raised full-year revenue guidance to $602-610 million, reflecting 12.5-14% growth over 2025. Adjusted EBITDA guidance was increased to $85-89 million. AtriCure also reported its BoxX-NoAF clinical study surpassed 50% enrollment ahead of schedule.
AtriCure, a medical device company focused on atrial fibrillation treatments, reported first-quarter 2026 revenue of $141.2 million, up 14.3% year over year and exceeding analyst estimates by 1.4%. Growth was driven by a 28% increase in the pain management segment, led by its cryoSPHERE MAX probe. The company announced it has accelerated its BoxX-NoAF clinical trial timeline by 12 months, with patient enrollment now expected to complete by year-end and results potentially available in 2027 instead of 2028. The trial tests a minimally invasive procedure for treating atrial fibrillation. Following the results, Needham reiterated its Buy rating with a $45 price target on 6 May, citing the accelerated trial timeline as a major development that could unlock significant new market opportunities.
AtriCure expects 12% to 14% revenue growth in 2026, driven by recent and upcoming product launches including cryoSPHERE MAX, cryoXT and new appendage-management devices. President and CEO Michael Carrel and CFO Angela Wirick discussed the outlook at a Bank of America fireside chat, following 15% revenue growth in 2025. The company's EnCompass ablation platform and AtriClip continue to show significant runway, with executives citing a large untapped cardiac-surgery market and strong surgeon adoption. A next-generation V-Clip appendage product is expected in 2027. AtriCure guided 2026 adjusted EBITDA at $80 million to $82 million whilst maintaining profitability improvements. The cryoXT device, targeting lower-extremity amputations, had a soft launch in late 2025 and is expected to contribute more meaningfully in the second half of 2026.